98 related articles for article (PubMed ID: 21486609)
1. A comparison of mycophenolate mofetil with mycophenolate sodium in renal transplant recipients on tacrolimus-based treatment.
Aptaramanov B; Seyahi N; Alagoz S; Pekmezci S; Ataman R; Tasci H; Serdengecti K
Transplant Proc; 2011 Apr; 43(3):833-6. PubMed ID: 21486609
[TBL] [Abstract][Full Text] [Related]
2. A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipients.
Kamar N; Rostaing L; Cassuto E; Villemain F; Moal MC; Ladrière M; Barrou B; Ducloux D; Chaouche K; Quéré S; Di Giambattista F; Be F
Clin Nephrol; 2012 Feb; 77(2):126-36. PubMed ID: 22257543
[TBL] [Abstract][Full Text] [Related]
3. Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patients.
Salvadori M; Holzer H; Civati G; Sollinger H; Lien B; Tomlanovich S; Bertoni E; Seifu Y; Marrast AC;
Clin Nephrol; 2006 Aug; 66(2):112-9. PubMed ID: 16939067
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolic acid dose reductions result in poor long-term renal allograft survival: comparison between mycophenolate sodium and mycophenolate mofetil.
Laftavi MR; Hai F; Laftavi H; Feng L; Said M; Patel S; Kohli R; Alnimri M; Dayton M; Pankewycz O
Transplant Proc; 2011 Mar; 43(2):478-81. PubMed ID: 21440738
[TBL] [Abstract][Full Text] [Related]
5. A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children.
Yao G; Albon E; Adi Y; Milford D; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2006 Dec; 10(49):iii-iv, ix-xi, 1-157. PubMed ID: 17134597
[TBL] [Abstract][Full Text] [Related]
6. Improved gastrointestinal symptoms and quality of life after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus.
Hwang HS; Hyoung BJ; Kim S; Oh HY; Kim YS; Kim JK; Kim YH; Kim YL; Kim CD; Shin GT; Yang CW
J Korean Med Sci; 2010 Dec; 25(12):1759-65. PubMed ID: 21165291
[TBL] [Abstract][Full Text] [Related]
7. Low-dose mycophenolate mofetil in tablet form or capsule form combined with tacrolimus in the early period after kidney transplantation: a prospective randomized trial
.
Lee SH; Kim CD; Huh KH; Cho BH; Ju MK; Lee DR; Cho HR; Park JW; Lee JJ; Lee S; So BJ; Oh CK; Kim YS
Clin Nephrol; 2016 Dec; 86 (2016)(12):319-327. PubMed ID: 27781419
[TBL] [Abstract][Full Text] [Related]
8. Influence of Proton Pump Inhibitors on Mycophenolic Acid Pharmacokinetics in Patients With Renal Transplantation and the Relationship With Cytochrome 2C19 Gene Polymorphism.
Ciftci HS; Karadeniz MS; Tefik T; Caliskan Y; Yazıcı H; Demir E; Turkmen A; Nane I; Oguz FS; Aydin F
Transplant Proc; 2017 Apr; 49(3):490-496. PubMed ID: 28340819
[TBL] [Abstract][Full Text] [Related]
9. Comparison of transplanted kidney function in patients on two different doses of mycophenolate mofetil.
Khosroshahi HT; Nahali A; Gojazadeh M; Shoja MM
Transplant Proc; 2006 Sep; 38(7):2035-7. PubMed ID: 16979991
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes in African American kidney transplant recipients under contemporary immunosuppression: a four-yr analysis of the Mycophenolic acid Observational REnal transplant (MORE) study.
Narayanan M; Pankewycz O; Shihab F; Wiland A; McCague K; Chan L
Clin Transplant; 2014 Feb; 28(2):184-91. PubMed ID: 24372743
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of tolerability of enteric-coated mycophenolate sodium versus mycophenolate mofetil in de novo renal transplantation.
Pacheco e Silva Filho A; Manfro RC; Contieri FL; Mazzali M; Garcia VD; Carvalho Dde B; David S; Machado P; Rodrigues CA
J Bras Nefrol; 2015; 37(3):291-6. PubMed ID: 26398638
[TBL] [Abstract][Full Text] [Related]
12. Renal Transplant Acute Rejection with Lower Mycophenolate Mofetil Dosing and Proton Pump Inhibitors or Histamine-2 Receptor Antagonists.
Patel KS; Stephany BR; Barnes JF; Bauer SR; Spinner ML
Pharmacotherapy; 2017 Dec; 37(12):1507-1515. PubMed ID: 28976570
[TBL] [Abstract][Full Text] [Related]
13. Association of mycophenolic acid dose with efficacy and safety events in kidney transplant patients receiving tacrolimus: an analysis of the Mycophenolic acid Observational REnal transplant registry.
Doria C; Greenstein S; Narayanan M; Ueda K; Wiland A; McCague K; Sankari B; Chan L
Clin Transplant; 2012; 26(6):E602-11. PubMed ID: 23121178
[TBL] [Abstract][Full Text] [Related]
14. Adverse drug reaction driven immunosuppressive drug manipulations: a single-center comparison of enteric-coated mycophenolate sodium vs. mycophenolate mofetil.
Hardinger KL; Hebbar S; Bloomer T; Murillo D
Clin Transplant; 2008; 22(5):555-61. PubMed ID: 18394000
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Mizoribine Combined With Tacrolimus in Living Donor Kidney Transplant Recipients: 3-Year Results by a Chinese Single Center Study.
Shi Y; Liu H; Chen XG; Shen ZY
Transplant Proc; 2019 Jun; 51(5):1337-1342. PubMed ID: 31155174
[TBL] [Abstract][Full Text] [Related]
16. Impact of maintenance immunosuppressive therapy on the fecal microbiome of renal transplant recipients: Comparison between an everolimus- and a standard tacrolimus-based regimen.
Zaza G; Dalla Gassa A; Felis G; Granata S; Torriani S; Lupo A
PLoS One; 2017; 12(5):e0178228. PubMed ID: 28542523
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of mycophenolate sodium (MPS) and mycophenolate mofetil (MMF) with and without cyclosporine in rat transplantation models.
Schuurman HJ; Pally C; Fringeli-Tanner M; Papageorgiou C
Transplantation; 2001 Dec; 72(11):1776-83. PubMed ID: 11740387
[TBL] [Abstract][Full Text] [Related]
18. Improved gastrointestinal symptom burden after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in kidney transplanted children.
Pape L; Ahlenstiel T; Kreuzer M; Ehrich JH
Pediatr Transplant; 2008 Sep; 12(6):640-2. PubMed ID: 18798359
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerance of sodium mycophenolate in patients after renal transplantation--an observational study.
Gozdowska J; Urbanowicz A; Baczkowska T; Pazik J; Matlosz B; Cieciura T; Szmidt J; Chmura A; Durlik M
Transplant Proc; 2009 Oct; 41(8):3016-8. PubMed ID: 19857665
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular risk factors in renal transplant patients after switch from standard tacrolimus to prolonged-release tacrolimus.
Sessa A; Esposito A; Iavicoli G; Lettieri E; Ragosta G; Rossano R; Capuano M
Transplant Proc; 2012 Sep; 44(7):1901-6. PubMed ID: 22974866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
